Pieris Pharmaceuticals (NASDAQ: PIRS) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Pieris Pharmaceuticals to similar businesses based on the strength of its profitability, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.


This table compares Pieris Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pieris Pharmaceuticals -321.83% -221.93% -42.02%
Pieris Pharmaceuticals Competitors -5,351.80% -434.25% -39.90%

Valuation & Earnings

This table compares Pieris Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Pieris Pharmaceuticals $5.83 million -$22.79 million -8.41
Pieris Pharmaceuticals Competitors $284.28 million $34.29 million 133.33

Pieris Pharmaceuticals’ rivals have higher revenue and earnings than Pieris Pharmaceuticals. Pieris Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Pieris Pharmaceuticals and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pieris Pharmaceuticals 0 0 3 0 3.00
Pieris Pharmaceuticals Competitors 848 3197 11597 230 2.71

Pieris Pharmaceuticals currently has a consensus target price of $9.00, suggesting a potential upside of 46.58%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.88%. Given Pieris Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts clearly believe Pieris Pharmaceuticals is more favorable than its rivals.

Institutional & Insider Ownership

50.5% of Pieris Pharmaceuticals shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 4.1% of Pieris Pharmaceuticals shares are held by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Pieris Pharmaceuticals has a beta of -76.07, indicating that its share price is 7,707% less volatile than the S&P 500. Comparatively, Pieris Pharmaceuticals’ rivals have a beta of 0.55, indicating that their average share price is 45% less volatile than the S&P 500.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company’s second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.

Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.